Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) presented new data that support the clinical and safety profile of their long-lasting recombinant factor VIII candidate ELOCTATE for hemophilia A. Five platform and oral presentations at the XXIV…
Source: Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A
